Psychedelic Therapy Research: What the Evidence Shows

Psychedelic therapy research has produced some of the most significant psychiatric outcomes documented in decades. Ibogaine — the primary alkaloid from Tabernanthe iboga — recorded 88% reductions in PTSD symptoms, 87% in depression, and 81% in anxiety at one month in a controlled Stanford study. 5-MeO-DMT research is earlier but consistent in direction. Neither compound is approved for medical use, and neither requires a clinical trial to access legally in Canada.

What the Ibogaine Research Shows

The Stanford study published in Nature Medicine in February 2023 is the most-cited recent finding in ibogaine research. Thirty special operations veterans with PTSD, traumatic brain injury, and treatment-resistant depression received ibogaine treatment and were assessed one month later:

• PTSD symptoms: 88% average reduction
• Depression symptoms: 87% average reduction
• Anxiety symptoms: 81% average reduction

For context: conventional antidepressant research considers a 50% reduction in depression scores a strong response. These are not marginal gains.

Ibogaine's mechanism differs from every current approved treatment. It acts on opioid, dopamine, NMDA, and serotonin receptors simultaneously — a profile unlike SSRIs, SNRIs, or any approved antidepressant. It also triggers release of GDNF (glial cell line-derived neurotrophic factor), a growth factor associated with neuroplasticity that stays elevated for weeks to months after a single dose. This metabolite persistence — through noribogaine, ibogaine's primary active metabolite — explains why the effects outlast the ceremony itself. The mechanism is covered in more detail in our ibogaine for PTSD article.

The ibogaine evidence base for opioid addiction is older and larger than the PTSD data. Observational studies and practitioner records going back decades consistently document rapid interruption of opioid withdrawal — within 24–36 hours — and significant reductions in craving that persist beyond the ceremony. No approved medication produces this outcome through the same mechanism. The Stanford study brought PTSD into the mainstream conversation, but addiction research was already substantial.

What the 5-MeO-DMT Research Shows

5-MeO-DMT — found in the Sonoran Desert toad (Incilius alvarius) and in synthetic form — is a distinct compound from ibogaine. Its active period runs 20–45 minutes rather than 12–24 hours. The experience it produces is ego dissolution rather than narrative memory review. No specific memories surface, no biographical content appears. The self temporarily ceases to function as an organising structure.

The research base for 5-MeO-DMT is smaller than ibogaine's. Studies indexed in peer-reviewed psychopharmacology journals document significant reductions in depression and anxiety ratings following a single naturalistic session, sustained at four-week follow-up. Research at Johns Hopkins with synthetic 5-MeO-DMT has produced similar findings.

5-MeO-DMT and ibogaine are not alternatives to each other — they address overlapping conditions through different mechanisms, and some people work with both in sequence. How the two medicines are used together is covered separately. The research base for each is growing. The direction is consistent.

One thing 5-MeO-DMT is not: a lighter version of ibogaine. It is shorter, not gentler. The intensity of ego dissolution in 20–45 minutes carries its own demands, and the absence of narrative content makes integration harder for some people — not simpler.

The $50 Million Texas Clinical Trials

Following the Stanford study, $50 million in funding was committed to clinical ibogaine trials — the largest single investment in ibogaine research ever assembled. The institutions involved are UTMB (University of Texas Medical Branch), UTHealth Houston, Texas A&M University, and Baylor University.

This represents a transition from proof-of-concept research to formal Phase II and Phase III clinical investigation with the participant numbers and controls that typically precede regulatory consideration. Results will arrive within the next several years.

What it does not mean is that ibogaine treatment is unavailable now. The clinical trials will produce the data needed for FDA consideration or policy revision in the United States. Canada's legal access — ibogaine is not listed under the Controlled Drugs and Substances Act — means the option exists now, without waiting for trial enrolment or regulatory change.

50 Years of Scheduling Law

Ibogaine was placed on Schedule I in the United States in 1970. That decision was made before clinical research into its therapeutic effects existed — the pharmacology was not understood, the GDNF mechanism was not identified, and no controlled study had been conducted. The scheduling decision preceded the science.

The evidence accumulated since then — despite inadequate funding, despite the logistical obstacles Schedule I status places on research, despite 50 years of structural difficulty — is remarkably consistent in direction. Practitioners, observational studies, the Stanford publication, and now the Texas trial commitment all point in the same direction.

MAPS (Multidisciplinary Association for Psychedelic Studies) has documented these constraints in peer-reviewed commentary. The scheduling decision was a policy choice, not a scientific verdict. The full context of why ibogaine was scheduled and what has changed is covered in our article on ibogaine's legal status.

The veterans in the Stanford study had already been through the VA system, through approved medications, through evidence-based programmes. The medicine that produced 88% PTSD symptom reductions was not available to them through any US provider. That is the cost of the policy.

How to Read These Numbers Honestly

The Stanford study is important. It is also limited — and citing the numbers without those limitations is not honest.

Thirty veterans is not a definitive population. The absence of a placebo arm is a genuine methodological limitation. The population was specific: treatment-resistant special operations veterans, not a representative sample of everyone who might seek ibogaine treatment. One study, one population, no control group.

The numbers are compelling enough to stand on their own with those caveats included. What makes the Stanford findings meaningful is not that they stand alone — it's that they are consistent with practitioner observations accumulated over decades and with the smaller observational studies that preceded them. The direction is consistent. The magnitude is large. The Texas trials will confirm or qualify those numbers with a more rigorous design.

Special operations veterans are not, as a population, people who enter things expecting them to work. They had been through the VA. Many were sceptical. The Stanford study documented what practitioners had been observing for years — that ibogaine produces changes in this population that conventional approaches do not. The scepticism those veterans brought into the study makes the results harder to attribute to placebo, not easier.

Who This Research Does Not Apply To

The people who most urgently want access to this treatment are not always the people it is safe for. That gap is the most important thing to understand before a screening conversation.

Cardiac contraindications are the most serious. Ibogaine prolongs the QT interval — a measure of cardiac electrical activity. In people with pre-existing QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction, this can produce fatal arrhythmia. Every documented ibogaine death has involved either a cardiac contraindication not identified in advance, or a contraindicated medication not disclosed. EKG and cardiovascular assessment are required before iboga ceremony — not as bureaucracy, but as the test that determines whether ceremony is safe for you specifically. Any provider who skips this step is not operating safely.

Absolute contraindications for ibogaine ceremony include:

• QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction
• Current SSRIs or SNRIs — a supervised taper is required first; the serotonin syndrome risk is real and potentially fatal, and no case is an exception
• Methadone — a specific transition protocol is required
• Active psychosis or schizophrenia spectrum disorder
• Severe liver or kidney disease
• Lithium and certain other psychiatric medications
• Pregnancy

For 5-MeO-DMT: lithium is an absolute contraindication — seizure and cardiac risk. Personal or family history of psychotic spectrum disorder is also a disqualifier. The full contraindications list covers medications and conditions that require individual assessment before a decision is made.

Someone in acute psychiatric crisis is not an appropriate candidate for either medicine, regardless of how compelling the research is or how urgently they feel they need it. The medicine amplifies what is present. Entering ceremony in a state of acute instability does not produce stability.

If someone is primarily seeking a profound experience or a shortcut to insight, iboga will not deliver what they came for. The medicine tends to show people what they have been avoiding — not what they were hoping to find.

Is This Research Relevant to Your Situation?

If you are following psychedelic therapy research because you or someone close to you has not responded to conventional treatment for PTSD, addiction, or depression, the research is relevant — but what it means for a specific individual's situation requires a screening conversation, not a literature review.

The ceremony page covers what iboga and 5-MeO-DMT ceremony at Transcend involves. The FAQ addresses common questions about screening, cost, and legal access. Applications receive a personal response within 2–3 business days at jake.nylund@gmail.com.

The $50 million Texas trials will produce better data within the next few years. Legal access in Canada means the option exists now for those who meet the medical criteria. Vancouver is approximately 45 minutes from the US border.

The research is not a reason to pursue this carelessly. It is a reason to pursue it with accurate information about what the evidence shows, what it does not yet show, and what screening is required before it can safely apply to you specifically.